Maxim upgraded Theriva Biologics (TOVX) to Buy from Hold with a $1 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TOVX:
- Theriva Biologics Advances VCN-01 Into Pivotal Phase 3
- Theriva Biologics announces outcome of Type B End-of-Phase 2 meeting with FDA
- Theriva Biologics price target lowered to $4 from $7 at Alliance Global
- Theriva Biologics reports FY25 EPS ($2.08) vs. ($19.03) last year
- Theriva Biologics sees cash runway into 1Q27